KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Opko Health (OPK) EBITDA (2016 - 2025)

Opko Health's EBITDA history spans 16 years, with the latest figure at -$38.3 million for Q4 2025.

  • For Q4 2025, EBITDA changed N/A year-over-year to -$38.3 million; the TTM value through Dec 2025 reached -$117.4 million, changed N/A, while the annual FY2025 figure was -$117.4 million, 22.79% up from the prior year.
  • EBITDA reached -$38.3 million in Q4 2025 per OPK's latest filing, down from $48.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $48.1 million in Q3 2025 to a low of -$87.8 million in Q3 2022.
  • Average EBITDA over 5 years is -$31.6 million, with a median of -$55.3 million recorded in 2022.
  • Peak YoY movement for EBITDA: plummeted 977.86% in 2024, then skyrocketed 238.04% in 2025.
  • A 5-year view of EBITDA shows it stood at -$63.1 million in 2021, then increased by 12.39% to -$55.3 million in 2022, then dropped by 24.93% to -$69.0 million in 2023, then skyrocketed by 120.59% to $14.2 million in 2024, then plummeted by 369.53% to -$38.3 million in 2025.
  • Per Business Quant, the three most recent readings for OPK's EBITDA are -$38.3 million (Q4 2025), $48.1 million (Q3 2025), and -$60.0 million (Q2 2025).